SCHEMBL5437303

SCHEMBL5437303

COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCN3CCOCC3)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.54
PPARG P37231 3/20 0.54
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 1/20 0.52
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
BCHE P06276 1/20 0.51
ACHE P22303 1/20 0.51
GAA P10253 2/20 0.50
MMP1 P03956 1/20 0.50
MMP9 P14780 1/20 0.50
MMP13 P45452 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
POLB P06746 1/20 0.50
LTA4H P09960 1/20 0.50
DRD3 P35462 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5432386 0.82 POLB (0.51) KDM4EALDH1A1KEAP1NFE2L2BCHE
SCHEMBL5437274 0.80 PPARA (0.46) PPARAPPARGLTA4HDRD3
SCHEMBL5428793 0.80 PPARA (0.52) PPARAPPARGKDM4EALDH1A1DRD3
SCHEMBL5428115 0.78 PPARA (0.56) PPARAPPARGKDM4EALDH1A1
SCHEMBL5441860 0.78 PPARA (0.56) PPARAPPARGSMN1; SMN2
SCHEMBL5434312 0.77 PPARA (0.56) PPARAPPARGALDH1A1SMN1; SMN2
SCHEMBL5423669 0.77 PPARA (0.54) PPARAPPARGKDM4EALDH1A1BCHE
SCHEMBL5434311 0.76 PPARA (0.52) PPARAPPARGALDH1A1DRD3
SCHEMBL3569060 0.75 LTA4H (0.67) KDM4EALDH1A1GAASMN1; SMN2LTA4H
SCHEMBL10186223 0.75 PPARA (0.55) PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 PPARA 990/4885PPARG 615/4885KDM4E 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.